Weight-Loss Drugs May Reduce Buildup of Alzheimer's Proteins
4 hours ago
- #Preclinical Research
- #Alzheimer's Disease
- #GLP-1 Drugs
- A new review links GLP-1 drugs to limiting dementia-related molecular hallmarks in preclinical studies.
- The review assessed 30 studies, with most showing reductions in amyloid-beta plaques and tau tangles in models.
- Potential mechanisms include reducing inflammation, improving insulin signaling, and altering amyloid-beta production.
- Liraglutide was most consistent in reducing harmful proteins, while exenatide had the smallest effect.
- Human trials are limited and mixed, with no clear evidence yet of cognitive decline prevention.
- GLP-1 drugs are seen as candidates for future Alzheimer's prevention trials, but more research is needed.